Monoclonal antibody · Inhibitor of CD39 (ENTPD1) · developed by Arcus Biosciences
Afivastobart is an Fc-silent IgG1 human monoclonal antibody that binds the cell surface ectonucleosidase CD39 (ENTPD1). By blocking CD39, it prevents the breakdown of extracellular ATP to AMP, raising immunogenic ATP and lowering immunosuppressive adenosine in the tumor microenvironment. It is studied in multiple solid tumors, including non-small cell lung cancer, renal cell carcinoma, and triple negative breast cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05891171 | Phase 1 | Advanced Cancer | Active not recruiting | RCUS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced CancerAdvanced MalignanciesBladder CancerCervical CancerEsophageal CancerGastric CancerGastroesophageal-junction Cancer (GEJ)Head and Neck Squamous Cell Carcinoma (HNSCC)Non-Small Cell Lung Cancer (NSCLC)Ovarian CancerRenal Cell Carcinoma (RCC)Triple Negative Breast Cancer (TNBC)
Updated Oct 25, 2026. Something wrong or missing? Report it on the RCUS page.
See RCUS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RCUS catalysts and pipeline →